A new nutraceutical to improve tolerance of adjuvant chemotherapy

Introduction. Treatment of malignant neoplasms often requires adjuvant chemotherapy (ACT). In real-life clinical practice, a high proportion of patients develop serious toxicities of anticancer therapy. Thus, the need to reduce treatment toxicity while maintaining the same dose levels of chemotherapeutic agents is a pressing challenge in oncology. This article presents the results of the study assessing the effects of the complex nutraceutical Oncoxin on ACT tolerability. Materials and methods. The study included 133 patients aged 50 to 70 years with stage IIB - IIIC gastric cancer or stage IIB - IIIA non-small-cell lung cancer; 84 patients received Oncoxin, and 49 were in the control group. Results. The study revealed that after two weeks, patients receiving Oncocoxin had a twice higher chance of significant (obvious) improvement in their quality of life (ESAS questionnaire) compared to the control group: OR 2.07 [95 % CI 1.00 - 4.29]. By the end of the follow-up period (3 weeks), patients receiving Oncoxin had a significantly higher albumin level compared to the control group (38.1 [95 % CI 37.1 - 39.1] g / L and 35.5 [95 % CI 33.9 - 37.0], р = 0.03, respectively). Moreover, the use of Oncoxin allowed significant reducing ACT-related liver toxicity. Conclusions. This study conducted within our current clinical practice showed for the first time a high efficacy of Oncoxin in improving the quality of life of patients and reducing ACT toxicity